• Conference Recording
  • On-Demand
  • Special Populations
Recorded during Overcoming Obesity 2021. CME/CE Expiration Date: 9/26/24
  • 1.00 AMA PRA Category 1 Credit
  • Conference Recording
  • On-Demand
  • Pharmacotherapy
As published and described in Obesity Pillars (i.e., the official journal of the Obesity Medicine Association), excessive weight reduction is an emerging challenge that sometimes arises with approv
  • 1.00 AMA PRA Category 1 Credit
  • Conference Recording
  • On-Demand
  • Pharmacotherapy
OMA 2023 Spring Summit: Overcoming Barriers to Initiating Anti-Obesity Medications (On Demand)CME/CE Expiration Date: 4/23/26
  • 1.00 AMA PRA Category 1 Credit
  • Conference Recording
  • On-Demand
  • Special Populations
Obesity is a disease that disproportionately affects women. Those from ethnic/racial minorities and those who live in poverty are often more severely affected.
  • 1.00 AMA PRA Category 1 Credit
  • Conference Recording
  • On-Demand
  • Special Populations
In this session, speaker will deliver current endocrine society guidelines on gender affirming therapies and the association of obesity with high dose reproductive hormone initiation.
  • 1.00 AMA PRA Category 1 Credit
  • Conference Recording
  • On-Demand
  • Pharmacotherapy
A core component of obesity treatment includes recognition of weight promoting medications and their alternatives.
  • 1.00 AMA PRA Category 1 Credit
  • Conference Recording
  • On-Demand
  • Surgery
Alicia Shelly, MD will discuss the prevalence and etiologies of weight regain after bariatric surgery.
  • 1.00 AMA PRA Category 1 Credit
  • Conference Recording
  • On-Demand
  • Practice Management
This presentation will provide an overview of the evidence basis for using continuous glucose monitoring (CGM) in patients with obesity.
  • 1.00 AMA PRA Category 1 Credit
  • Conference Recording
  • On-Demand
  • Behavioral Modification
The challenges of treating co-morbid binge eating disorder and obesity".
  • 1.00 AMA PRA Category 1 Credit
  • Conference Recording
  • On-Demand
  • Adiposity Related Diseases
This session will focus on the management of non-alcoholic fatty liver disease (NAFLD) with a particular emphasis on the role of GLP-1 agonists and SGLT-2 inhibitors in treating this condition.
  • 1.00 AMA PRA Category 1 Credit

Pages